RxDoctor Payments Data

Kendrick Wright

Family · Phoenix, AZNPI 1326675166

Payments from drug & device makers

$574in general payments, 2019–2025

Across 25 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hikma Pharmaceuticals USA$152
  • Vertos Medical, Inc.$115
  • Collegium Pharmaceutical, Inc.$81
  • Sanofi-aventis U.S. LLC$35
  • Nalu Medical, Inc.$35
  • Biohaven Pharmaceuticals, Inc.$31
  • plus $124 from 6 others

What the payments were for

  • Food & beverage$49085%
  • Education$8415%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$574 in reported general payments places this provider in the 55th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$61,167
Medicare patients
218
Services billed
782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl536$11,126
Buprenorphine42$9,387
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen214$7,908
Xtampza ErOxycodone Myristate34$7,359
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen213$6,794
OxycontinOxycodone Hcl22$4,991
MovantikNaloxegol Oxalate14$4,907
Lidocaine-PrilocaineLidocaine/Prilocaine24$4,700
Pregabalin115$4,440
Gabapentin177$2,564
Tramadol Hcl82$1,576
Morphine Sulfate ErMorphine Sulfate82$1,503
Morphine Sulfate66$1,476
Acetaminophen-CodeineAcetaminophen With Codeine61$1,319
Fentanyl12$783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$152$10,864108 claims
Collegium Pharmaceutical, Inc.Xtampza Er$81$7,35934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →